FSSAI send notices to Dr Reddy's, Nestle Health Science, Amazon, Flipkart over misleading protein supplement

What did FSSAI accuse the companies and e-commerce platforms of doing with Celevida GLP?

FSSAI said Celevida GLP was advertised with claims that could mislead consumers about its benefits. The regulator objected to statements about muscle strength, immunity support, energy metabolism and preserving lean muscle during GLP-1/GIP therapies. The issue matters because such wording may make a supplement appear suitable for a specific medical or physiological condition.

The product was promoted as “high protein support for lean muscle preservation during GLP-1/GIP therapies.” Its brand name, Celevida GLP, also linked it directly with those therapies. FSSAI said claims such as “Helps Maintain Lean Muscle,” “support muscle strength” and “preserve lean mass” could imply protection against muscle loss during weight loss or therapy.

FSSAI asked the companies to explain why action should not be taken. It also issued notices to online sellers and marketplaces involved in selling the product. Amazon said the product was no longer available on its marketplace, while the companies had not yet responded.

How many companies and online platforms were named in the notices, and which ones were they?

The article names six entities in the notices concerning Celevida GLP. The companies were Dr Reddy’s, Nestle Health Science and Tirupati Wellness. The online platforms were Flipkart, Amazon and Netmeds. FSSAI’s action covered both the product-related businesses and marketplaces where the product was advertised or sold.

The notices followed concerns about the product’s marketing and packaging. FSSAI questioned claims about muscle strength, immunity support, energy metabolism and lean-muscle preservation. It also flagged the representation “imported from Europe for purity.” The regulator said the product’s name and therapy-related claims created a misleading association with GLP-1/GIP treatments.

The article separately names Nex International and Shreyash Retail in enforcement over other food-safety matters. Those actions involved pesticide-contaminated loose raisins and expired or rotten food. Therefore, they are additional enforcement cases, not part of the six entities listed for Celevida GLP notices.

What is a GLP-1 or GIP therapy, and why might it be associated with weight loss, diabetes treatment, and muscle preservation?

GLP-1 and GIP therapies are treatments associated in the article with weight-loss and diabetes drugs. The article identifies them as therapies taken by some people in India and says Celevida GLP was marketed for people using them. It does not provide a detailed medical definition or explain how either therapy works.

The association with muscle preservation came from the product’s marketing. Celevida GLP was described as a high-protein powder supporting nutrition and muscle-mass maintenance during GLP-1/GIP therapies. Its advertising used wording such as “high protein support for lean muscle preservation” and “preserve lean mass.” These claims connected the supplement to a specific treatment context.

FSSAI objected because the association could imply that the product was suitable for a particular physiological condition or could mitigate lean-body-mass loss. The article does not establish that the product provides those effects. It reports only that FSSAI considered the wording potentially misleading.

Why did FSSAI consider claims such as “preserve lean mass” and “support muscle strength” potentially misleading?

FSSAI considered the claims potentially misleading because they appeared to promise more than general nutritional support. The wording could suggest that Celevida GLP helps prevent or reduce loss of lean body mass during weight loss or GLP-1/GIP therapy. Such a suggestion may influence consumers who are taking those therapies or expecting rapid weight loss.

The product was advertised as “high protein support for lean muscle preservation during GLP-1/GIP therapies.” Other statements included “Helps Maintain Lean Muscle,” “support muscle strength” and “preserve lean mass.” FSSAI said these claims seemingly implied that the product might mitigate muscle loss. Its name, Celevida GLP, reinforced the connection with the therapies.

The regulator also said the claims implied suitability for a specific physiological condition. FSSAI asked the companies to explain why action should not be taken. The article does not report a final finding that the product actually causes, prevents or treats muscle loss.

What could happen to Dr Reddy’s, Nestle Health Science, the seller, and the marketplaces if FSSAI finds the claims or listings non-compliant?

FSSAI issued notices asking the companies to explain why action should not be taken. If the regulator finds the advertising, packaging or product claims non-compliant, the businesses could face regulatory action under the applicable food-safety framework. The article does not specify the exact penalty that would follow or report a final decision against Dr Reddy’s or Nestle Health Science.

The seller and marketplaces could also face consequences for offering or distributing the listing. FSSAI issued notices to Flipkart India and Amazon Seller Services for selling the product. Amazon said it operates as a marketplace for independent sellers and removes non-compliant listings when directed by regulators. It confirmed that Celevida GLP was no longer available there.

The article does not identify a final punishment for Tirupati Wellness, the seller, Flipkart or Netmeds in this case. It shows that removal and regulatory explanations are immediate steps. Further action would depend on FSSAI’s assessment of the responses and compliance.

What is FSSAI, and how does it regulate health supplements, food advertising, and online food sales in India?

The Food Safety and Standards Authority of India, or FSSAI, is the food regulator identified in the article. In this case, it examined Celevida GLP’s advertising, packaging representations and health-related claims. Its concern was whether the wording complied with food-safety and advertising requirements and whether it could mislead consumers.

FSSAI challenged claims about muscle strength, immunity support, energy metabolism and preserving lean muscle. It also flagged the statement “imported from Europe for purity.” The regulator issued notices to product-related companies and to online platforms, including Flipkart India and Amazon Seller Services, because the product was being sold through e-commerce channels.

The article shows several enforcement tools. FSSAI asked companies to explain why action should not be taken. In separate cases, it suspended a Flipkart seller’s licence over expired or rotten food and sanctioned prosecution against Nex International over pesticide-contaminated loose raisins. These examples show oversight of both food businesses and online sales.

How do protein supplements differ from medicines, and what evidence is normally needed before a product can claim to prevent muscle loss or provide a specific health benefit?

Protein supplements and medicines serve different product categories. A protein supplement is generally presented as a source of nutrients, while a medicine is intended to treat, prevent or manage a medical condition. The article describes Celevida GLP as a high-protein powder and complete nutrition product, but FSSAI objected when its marketing connected that product with a specific therapy and physiological condition.

A claim such as “preserve lean mass” suggests a targeted health effect, not merely the presence of protein. To support such a claim, a company would normally need credible evidence that the product itself produces the stated outcome in the relevant users and circumstances. Evidence should be appropriate to the claim, clearly presented and consistent with applicable regulatory requirements.

The article does not specify India’s evidence threshold or identify studies for Celevida GLP. It reports that FSSAI found the wording potentially misleading and sought explanations. The key implication is that nutrition claims should not be framed as treatment-related protection without adequate substantiation and compliant advertising.

Key Facts:

📌 FSSAI called the Celevida GLP advertising and claims non-compliant.

📌 The product was linked to GLP-1/GIP therapies and lean-muscle preservation.

📌 Amazon said the product was no longer available on its marketplace.

📌 Six entities were named in connection with the Celevida GLP notices.

📌 The named platforms were Flipkart, Amazon and Netmeds.

📌 Nex International and Shreyash Retail faced separate food-safety action.

📌 The article links GLP-1/GIP therapies with weight-loss and diabetes drugs.